- Home
- GMAB vs THC Comparison
GMAB vs THC Comparison
Compare GMAB & THC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- THC
- Stock Information
- Founded
- GMAB 1999
- THC 1967
- Country
- GMAB Denmark
- THC United States
- Employees
- GMAB N/A
- THC N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- THC Hospital/Nursing Management
- Sector
- GMAB Health Care
- THC Health Care
- Exchange
- GMAB Nasdaq
- THC Nasdaq
- Market Cap
- GMAB 17.4B
- THC 17.7B
- IPO Year
- GMAB N/A
- THC N/A
- Fundamental
- Price
- GMAB $30.42
- THC $193.66
- Analyst Decision
- GMAB Strong Buy
- THC Buy
- Analyst Count
- GMAB 6
- THC 19
- Target Price
- GMAB $40.40
- THC $220.33
- AVG Volume (30 Days)
- GMAB 2.4M
- THC 1.1M
- Earning Date
- GMAB 11-06-2025
- THC 10-28-2025
- Dividend Yield
- GMAB N/A
- THC N/A
- EPS Growth
- GMAB 132.41
- THC N/A
- EPS
- GMAB 25.10
- THC 14.57
- Revenue
- GMAB $3,845,670,022.00
- THC $20,846,000,000.00
- Revenue This Year
- GMAB $24.92
- THC $3.67
- Revenue Next Year
- GMAB $15.97
- THC $4.52
- P/E Ratio
- GMAB $11.82
- THC $13.24
- Revenue Growth
- GMAB 29.57
- THC N/A
- 52 Week Low
- GMAB $17.24
- THC $109.82
- 52 Week High
- GMAB $33.65
- THC $217.43
- Technical
- Relative Strength Index (RSI)
- GMAB 56.40
- THC 41.18
- Support Level
- GMAB $28.08
- THC $189.58
- Resistance Level
- GMAB $30.78
- THC $202.44
- Average True Range (ATR)
- GMAB 0.68
- THC 7.32
- MACD
- GMAB 0.10
- THC -1.92
- Stochastic Oscillator
- GMAB 84.63
- THC 11.34
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About THC Tenet Healthcare Corporation
Tenet Healthcare is a Dallas-based healthcare services organization. It operates acute and specialty hospitals (47 as of December 2024) and over 500 ambulatory surgery centers and other outpatient facilities across the US, primarily in the South. Through its Conifer segment, Tenet also provides revenue cycle management solutions.